聚乙二醇干扰素α联合利巴韦林为基础的治疗方案在中国慢性丙型肝炎治疗中的临床价值

C ＂lmical value of pegylated interferon-a plus ribavirin-based therapy in antiviral treatment of chronic hepatitis C in China

慢性丙型肝炎病毒感染是我国肝硬化以及肝细胞癌的病因之一。在直接抗病毒药物（DAAs）上市之前，我国慢性丙型肝炎的标准治疗方案为聚乙二醇干扰素α联合利巴韦林的PR方案。随着DAAs的不断上市，我国慢性丙型肝炎治疗已逐渐过渡为以PR为基础联合DAAs及无干扰素的全口服DAAs方案，使慢性丙型肝炎成为可治愈的疾病。现拟对以PR为基础治疗慢性丙型肝炎的优势和不足进行阐述，为我国丙型肝炎的治疗提供参考。

Chronic hepatitis C virus （HCV） infection is one of the most common causes of liver cirrhosis and hepatocellular carcinoma in China. The older standard treatment regimen for chronic hepatitis C was the pegylated interferon-alfa plus ribavirin（PR）. Now newer oral medications called direct antiviral agents （DAAs） has been gradually changed to PR-based DA.As and interferon-free, oral DAAs; making chronic hepatitis C a curable disease. This article intends to expound the advantages and disadvantages of PR-based therapy and provide reference for the treatment of chronic hepatitis C.